Georgina Rizik
Role: Associate
Sites: CDL-Rockies, CDL-Toronto, CDL-Vancouver
Stream: Cancer
Georgina Rizik is a Global Biotechnology & Healthcare Executive with over 25 years of experience scaling therapies, companies, and innovation ecosystems across Europe and North America. She operates at the intersection of science, commercialization, AI, and capital, grounded by clinical pharmacy practice and shaped by senior roles in Fortune 500 biopharma, a CEO mandate building a global life sciences innovation district, and ongoing advisory to early-stage biotechnology and AI-enabled healthcare companies, including engagement with capital allocators.
Georgina has held commercial leadership positions at Roche, Novartis, and Boehringer Ingelheim, driving enterprise strategy for transformative oncology therapies and franchises. She consistently achieved strong P&L performance on portfolios ranging from $150M to over $1B, distinguished by her focus on patient outcomes, while leading and mobilizing global teams in complex, highly regulated environments.
In her most recent executive mandate as CEO of SC1, London’s Life Sciences Innovation District anchored by King’s College London and King’s Health Partners — one of the UK’s leading Academic Health Science Centres with £3.7B in turnover and 4.8M patients served annually — Georgina defined the strategy and built the operating model to scale innovation, drive investment readiness, and create long-term value. She worked closely with her Board and stakeholders across academia, biopharma, technology, government, and capital to forge high-impact public-private partnerships and a transatlantic commercialization bridge.
Georgina advises companies across biotech, healthtech, AI, and oncology at strategic inflection point on value proposition, go-to-market strategy, and capital deployment.
Recognized by INSEAD for her leadership in building global life sciences innovation ecosystems and named a PM360 ELITE 100 Strategist, Georgina holds a governance credential from Harvard Business School, advanced AI and Healthcare Transformation certificates from Harvard Medical School, an MBA from Kellogg-Schulich, and a BSc in Pharmacy from the University of Toronto.
Whether scaling global franchises, building innovation ecosystems, or advising frontier companies, Georgina consistently delivers exceptional results and value across geographies, sectors, and institutional boundaries. As science, AI, and capital converge to reshape how healthcare innovations are developed and delivered, she brings integrated commercial and strategic leadership, ecosystem architecture, and capital markets fluency to translate that complexity into strategic clarity — and to drive what comes next.